Scarica l'app Stockscreener
442.96
0.87%
-3.87
Pre-mercato:
442.10
-0.86
-0.19%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VRTX Giù?
Forum
Previsione
Frazionamento azionario
Vertex Pharmaceuticals Inc Borsa (VRTX) Ultime notizie
Kyverna vs. Vertex: Clinical-Stage Risk vs. Cash-Flow Stability in Biotech InvestingNews and Statistics - IndexBox
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026? - Yahoo Finance
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026? - The Motley Fool
Membranous Nephropathy Market Emerging as a High-Growth Healthcare Investment Space Through 2036 – DelveInsight | Roche, BeOne Medicines, Biogen, Vertex Pharma, AstraZeneca, Alexion Pharma, Climb Bio - Barchart.com
News | Not built for eternity: Design technique looks to avoid permanence - CoStar
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference - BioSpace
Assessing Vertex Pharmaceuticals (VRTX) Valuation After Mixed Recent Returns And Long Term Shareholder Gains - Yahoo Finance
FDA accepts Vertex's BLA for povetacicept in IgA nephropathy - MSN
VRTX Stock Quote Price and Forecast - CNN
Vertex Pharmaceuticals (VRTX) Reveals Promising Cystic Fibrosis Treatment Data - GuruFocus
Carmen R. Bozic sells shares at VRTX (NASDAQ: VRTX) - Stock Titan
Vertex Presents New Data on ALYFTREK ® at European Cystic Fibrosis Conference - Via TT
Wells Fargo Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $550 - Moomoo
Ixlayer rolls out digital acute pain management platform in collaboration with Vertex Pharmaceuticals - Fierce Healthcare
Fierce Biotech Layoff Tracker 2026: Fulcrum cuts 85% of staff; Novartis trims research team - Fierce Biotech
Two Beaten-Down Pharma Giants: Biotech’s Cyclical Turn Delivers Prime Dip-Buy Opportunities - NAI500
Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Sustained momentum drives Vertex Pharmaceuticals stock higher despite signs of overbought conditions - Traders Union
RBC Capital Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $543 - Moomoo
These 2 Cheap Biotech Stocks Offer Potential for Low-Beta Growth - AOL.com
The Best Stocks to Invest $500 in Right Now - AOL.com
Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10 - BioSpace
Insider Sell: Joy Liu Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus
MFS Core Equity Portfolio's Vertex Pharmaceuticals Inc(VRTX) Holding History - GuruFocus
Vertex (VRTX) legal chief sells 828 shares in pre-set 10b5-1 trade - Stock Titan
Vertex CEO joins Goldman Sachs healthcare fireside chat June 10 - Stock Titan
Vertex Pharma stock (US92532F1003): Insider sale by CMO draws focus as shares hold near recent level - AD HOC NEWS
Vertex (VRTX) Up 0.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Analysts’ Top Healthcare Picks: Vertex Pharmaceuticals (VRTX), Bicara Therapeutics Inc. (BCAX) - The Globe and Mail
Vertex Pharmaceuticals (VRTX): Company Profile, Stock Price, News, Rankings - Fortune
Vertex stock down nearly 8% in 3 months: Time to buy or stay cautious? - MSN
Madrigal Pharmaceuticals Could Become The Next Vertex - Seeking Alpha
Insider Sell: Carmen Bozic Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus
Vertex Pharmaceuticals Inc stock (US92532F1003): shares slip after insider sales and FDA update on p - AD HOC NEWS
Is Vertex Pharmaceuticals (VRTX) Offering An Opportunity After Recent Share Price Consolidation? - Yahoo Finance
Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Vertex Pharmaceuticals Inc Stock (VRTX) Closed Down by 3.03% on Jun 2: Facts Behind the Movement - TradingKey
Vertex Pharmaceuticals Insider Sold Shares Worth $888,300, According to a Recent SEC Filing - marketscreener.com
Vertex (VRTX) CMO executes 1,974-share planned sale, retains holdings - Stock Titan
Why is Vertex Pharmaceuticals stock down today? - Traders Union
Should FDA’s IgA Nephropathy BLA Acceptance for Povetacicept Reshape Vertex Pharmaceuticals’ (VRTX) Investment Narrative? - Yahoo Finance
FDA Accepts Vertex's BLA for Povetacicept in IgA Nephropathy - Yahoo Finance
Vertex Pharmaceuticals Inc stock (US92532F1003): insider sales and Q1 2026 figures in focus - AD HOC NEWS
Acute Pain Market Set for Strong Expansion Through 2036 Amid Rising Investment Interest – DelveInsight | Vertex Pharma, Heron Therapeutics, Neumentum, Cali Biosciences - Barchart.com
Vertex Pharma stock (US92532F1003): FDA accepts povetacicept filing as shares trade steady on Nasdaq - AD HOC NEWS
Vertex Pharmaceuticals stock: Is VRTX underperforming the healthcare sector? - MSN
Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy - BioSpace
Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
Vertex Pharmaceuticals shares dip amid rising selling pressure - Traders Union
Vertex Pharmaceuticals (NASDAQ: VRTX) insider Joy Liu reports share sales - Stock Titan
Vertex Pharmaceuticals Stock: Is VRTX Underperforming the Healthcare Sector? - Barchart.com
Vertex Pharmaceuticals (VRTX) Receives FDA BLA Acceptance for Po - GuruFocus
Vertex Stock Down Nearly 8% in 3 Months: Time to Buy or Stay Cautious? - Yahoo Finance
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
FDA accepts Vertex filing for IgAN drug povetacicept By Investing.com - Investing.com Australia
Vertex announces US FDA acceptance of biologics license application for accelerated approval of povetacicept in IgA nephropathy - marketscreener.com
VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX): Affordable Growth with Strong Fundamentals - ChartMill
Vertex Pharmaceuticals (VRTX) Q1 2026 Earnings Call Transcript - Fortune
Vertex Pharma stock (US92532F1003): Insider sales and Norges Bank stake highlight ownership dynamics - AD HOC NEWS
Committee Stocks On The Move: Uber And Vertex Pharma Dybala (RYo07l9B0s) - Mshale
Is Vertex Pharmaceuticals Successfully Diversifying Beyond Cystic Fibrosis - Kavout
Vertex Pharmaceuticals (VRTX) affiliate reports multiple share sales, proceeds listed - Stock Titan
Vertex Pharma stock (US92532F1003): Valuation stays in focus after a fresh move - AD HOC NEWS
VRTX: Renal franchise set to rival CF as new therapies and launches drive next phase of growth - TradingView
Vertex (VRTX) Announces Health Canada Acceptance of NDS for Suzetrigine - Insider Monkey
3.79%
0.26%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):